natgillin/translations-raw huggingface dataset:
Adverse reactions have been reported in 5-14% of patients receiving ciprofloxacin. 
O neželenih učinkih so poročali pri 5-14 % bolnikov, ki so prejemali ciprofloksacin.
increased blood sugar level (hyperglycaemia) Mental (psychiatric) disorders Rare: 
zvišana koncentracija sladkorja v krvi (hiperglikemija) Duševne (psihiatrične) motnje Redki:
Please inform your doctor when under treatment with Ciprofloxacin Kabi as the result of this test may be false. 
Obvestite zdravnika, da se zdravite z zdravilom Ciprofloxacin Kabi, saj je lahko rezultat tega testa lažen.
However, like a number of other quinolones ciprofloxacin is phototoxic in animals in exposure values relevant to humans. 
A tako kot številni drugi kinoloni je tudi ciprofloksacin pri živalih fototoksičen pri izpostavljenostih, ki so pomembne za človeka.
Since the risks for humans are unknown Ciprofloxacin Kabi must not be administered during pregnancy (see section 4.3). 
Ker tveganja za človeka niso znana, se Ciprofloxacina Kabi ne sme uporabljati med nosečnostjo (glejte poglavje 4.3).
Since ciprofloxacin is associated with very rare cases of QT prolongation (see section 4.8) caution should be exercised when treating patients at risk for torsade de pointes arrhythmia. 
Ker je ciprofloksacin povezan z zelo redkimi primeri QT podaljšanja (glejte poglavje 4.8) je potrebna previdnost pri zdravljenu bolnikov s tveganjem za aritmijo “torsade de pointes”.
If not used immediately, in-use storage times and conditions prior to use are the responsibility of the user. 
Če se raztopina ne uporabi takoj je za čas shranjevanja raztopine in pogoje shranjevanja odgovoren uporabnik.
It is also effective against Gram-positive organisms, such as staphylococci and streptococci. 
Učinkovit je tudi proti grampozitivnim mikroorganizmom, npr. stafilokokom in streptokokom.
Other preclinical effects were observed only at exposures that were sufficiently in excess of the maximum human exposure so that concern for human safety is negligible. 
Druge predklinične učinke so opažali samo pri izpostavljenostih, bistveno višjih od največje izpostavljenosti pri človeku.
When symptoms occur, such as yellowing of the skin or whites of the eyes, you should immediately consult your doctor. 
Če se pojavijo simptomi, kot je porumenelost kože ali beločnic, se takoj posvetujte z zdravnikom;
The elimination half-life of ciprofloxacin does not change with age. 
Eliminacijski razpolovni čas ciprofloksacina se s starostjo ne spreminja.
Ciprofloxacin inhibits CYP1A2 and thus may cause increased serum concentration of concomitantly administered substances metabolised by this enzyme (e.g. theophylline, clozapine, tacrine, ropinirol, tizanidine). 
Ciprofloksacin zavira CYP1A2 in tako lahko zviša serumsko koncentracijo tistih sočasno uporabljenih zdravil, ki se presnavljajo s tem encimom (npr. teofilin, klozapin, takrin, ropinirol, tizanidin).
In steady-state conditions the apparent distribution volume of ciprofloxacin is situated between 1,7 and 2,7 l/kg. 
Navidezni volumen porazdelitve ciprofloksacina v stanju dinamičnega ravnovesja je med 1,7 in 2,7 l/kg.
The frequencies of probably and/or possibly drug-related adverse events did not differ significantly between ciprofloxacin-treated patients and the comparator groups. 
Pogostost neželenih učinkov, ki so verjetno in/ali morda povezani z zdravili, pri bolniki zdravljenih s ciprofloksacinom ni kazala znatnih odstopanj glede na primerjalne skupine.
administration of 200 mg the plasma concentration is still higher than the MIC values of the majority of clinically relevant pathogens (approximately 0.1 µg/ml). 
Dvanajst ur po intravenski uporabi 200 mg je koncentracija v plazmi še vedno večja od MIK za večino klinično pomembnih patogenov (približno 0,1 µg/ml).
Pharmacotherapeutic group: Quinolone antibacterials (ATC code: J01MA02) Mode of action: 
Farmakoterapevtska skupina: kinolinske protimikrobne učinkovine (oznaka ATC: J01MA02).
The ciprofloxacin concentration in the sputum consists of 50-70% of the serum concentration. 
Koncentracija ciprofloksacina v sputumu je od 50 do 70 % tiste v serumu.
Use during pregnancy is contraindicated. 
Uporaba ciprofloksacina med nosečnostjo je kontraindicirana.
The applicant has submitted evidence demonstrating the historical development of ciprofloxacin resistance and the decreasing margin between antibiotic resistance and the MIC. 
Vlagatelj je predložil dokaze, ki so pokazali zgodovinski razvoj odpornosti na ciprofloksacin in manjšajočo se razliko med odpornostjo na antibiotike in minimalno zaviralno koncentracijo (MIC).
Because ciprofloxacin has some activity against Mycobacerium tuberculosis, false-negative cultures may occur when the specimens are obtained during ciprofloxacin treatment. 
Ker ima ciprofloksacin nekaj aktivnosti proti Mycobacterium tuberculosis, se lahko pojavi lažno negativna kultura pri odvzetih vzorcih med zdravljenjem s ciprofloksacinom.
In doing so the applicant/ MAH should discuss the data in relation to complicated and uncomplicated, upper and lower urinary tract infections. 
Pri tem bi moral vlagatelj/imetnik dovoljenja za promet podatke obravnavati tudi glede na zapletene in nezapletene oblike okužb ter okužb zgornjih in spodnjih sečil.
Ciprofloxacin Kabi should be administered via a short-term intravenous infusion (infusion into a vein) over 60 minutes. 
Ciprofloxacin Kabi je treba dajati kot kratkotrajno intravensko infuzijo (infuzija v veno) v času 60 minut.
When used simultaneously, ciprofloxacin may, in certain cases, increase the effect of glibenclamide (hypoglycaemia). 
Sočasno uporabljeni ciprofloksacin lahko v določenih primerih poveča učinek glibenklamida (hipoglikemija).
Ciprofloxacin Kabi has minor or moderate influence on the ability to drive and use machines. 
Ciprofloxacin Kabi ima blag ali zmeren vpliv na sposobnost vožnje in upravljanja s stroji.
Fresenius Kabi España S.A.c./ Marina 16-18, planta 17,E-08005 
Fresenius Kabi España S.A.c./ Marina 16-18, planta 17,E-08005 Barcelona, Španija
The following infections may be treated intravenously (via the blood) with Ciprofloxacin Kabi: 
Pri naslednjih okužbah pride v poštev intravensko (preko krvi) zdravljenje s Ciprofloxacinom Kabi:
The elimination half-life of ciprofloxacin after single or multiple oral dosage is between 3,4 and 6,9 hours. 
Eliminacijski razpolovni čas ciprofloksacina po posamičnem ali večkratnem peroralnem odmerjanju je med 3,4 in 6,9 ure.
Fresenius Kabi Pharma Portugal Lda., Avenida do Forte 3, Edifício Suécia IV, Piso 3, 2794-039 
Fresenius Kabi Pharma Portugal Lda., Avenida do Forte 3, Edifício Suécia IV, Piso 3, 2794-039 Carnaxide, Portugalska
The phototoxic, photomutagenic and photocarcinogenic potential of ciprofloxacin is comparable to that of other gyrase inhibitors. 
Fototoksični, fotomutageni in fotokancerogeni potencial ciprofloksacina je primerljiv tistemu pri drugih zaviralcih giraze.
• temporary pain and inflammation of the tendons, in particular of the Achilles tendon. 
• Začasna bolečina in vnetje kit, predvsem Ahilove kite.
Any unused solution and the bag should be adequately disposed of, in accordance with local requirements. 
Neuporabljeno raztopino in vrečko je potrebno odstraniti v skladu z lokalnimi predpisi.
Development of resistance to ciprofloxacin and other fluoroquinolones has been observed in staphylococci, especially methicillinresistant S. aureus, P. aeruginosa, E.coli and E. faecalis (see the sensitivity table). 
Pojav odpornosti proti ciprofloksacinu in drugim fluorokinolonom so zabeležili pri stafilokokih, zlasti za meticilin odporne S. aureus, P. aeruginosa, E. coli in E. faecalis (glejte desni stolpec v tabeli občutljivosti).
demonstrated clinical efficacy of 93% and bacterial eradication of 89%, but this was for the treatment of uncomplicated UTI (3) and efficacy of 91% (n=23) without development of resistance (2). 
Dve raziskavi peroralnih 100 mg odmerkov dvakrat dnevno sta pokazali 93 % klinično učinkovitost in 89 % eradikacijo bakterij, vendar le pri zdravljenju nezapletenih okužb sečil (3), in 91 % učinkovitost (n=23) brez pojava odpornosti (2).
Oral anticoagulants (e.g. warfarin) 
Peroralni antikoagulanti (tj. varfarin)
At haemodialysis or peritoneal dialysis only a modest amount of ciprofloxacin (less than 10%) is eliminated. 
S hemodializo ali peritonealno dializo se izloči le malo (manj kot 10 %) ciprofloksacina.
The total body clearance of ciprofloxacin is independent of the dose and remains unchanged in case of multiple administration. 
Celotni telesni očistek ciprofloksacina ni odvisen od odmerka in se v primeru večkratne uporabe ne spremeni.
Ask your doctor or pharmacist for advice before taking any medicine. 
Posvetujete se z zdravnikom ali farmacevtom, preden vzamete katerokoli zdravilo.
The ciprofloxacin level in the blood can be increased. 
Koncentracija ciprofloksacina v krvi se lahko zviša;
As with other fluoroquinolones, specific undesirable effects with regard to the central nervous system must be taken into account when using Ciprofloxacin Kabi. 
Tako kot pri drugih fluorokinolonih je treba tudi med uporabo Ciprofloxacina Kabi upoštevati neželene učinke na osrednje živčevje.
Due to the higher plasma levels in the elderly it is advisable to administer a doses based on creatinine clearance and severity of disease. 
Ker je koncentracija v plazmi pri starejših višja, je tem bolnikom priporočljivo dati odmerek prilagojen glede na očistek kreatinina in resnost bolezni.
The renal clearance constitutes 60%-70% of the total body clearance and is approximately 3 times higher than the creatinine clearance. 
Na račun ledvičnega očistka gre od 60 do 70 % celotnega telesnega očistka in je približno 3
You must NOT be given Ciprofloxacin Kabi in the following cases: 
Ne uporabljajte zdravila Ciprofloxacin Kabi v naslednjih primerih:
Commonly susceptible species Gram-positive species Bacillus anthracis Gram-negative aerobe species Citrobacter spp. 
Pogosto občutljive vrste Grampozitivne vrste Bacillus anthracis Gramnegativne aerobne vrste Citrobacter spp.
Ciprofloxacin has a rapid bactericidal effect, both in the growth phase and in the rest phase. 
Ciprofloksacin ima hiter baktericiden učinek, tako v fazi rasti kot v fazi mirovanja.
Ciprofloxacin can exacerbate the symptoms of this disease. 
Ciprofloksacin lahko poslabša simptome te bolezni.
three times daily as a maximum dose, a superior prevention of antibiotic resistance without a significant increase in adverse reactions in serious and life-threatening infections of other organ systems, there is no reason to conclude that this favourable risk/benefit profile would differ significantly in the treatment of complicated UTIs. 
- Ni razloga, da bi na podlagi objavljenih podatkov, ki so za predlagani najvišji odmerek 400 mg intravensko trikrat dnevno pokazali prednosti pri preprečevanju antibiotične odpornosti brez znatnega povečanja neželenih učinkov pri resnih in življenjsko nevarnih okužbah drugih organskih sistemov, zaključili, da bo ta profil tveganj/koristi znatno odstopal od tistega pri zdravljenju zapletenih okužb sečil.
Rare: syncope (fainting), vasodilation (heat stress). 
Redki: sinkopa (omedlevica), vazodilatacija (vročinski stres).
In very rare cases ventricular arrhythmia, QT interval prolongation and torsades de pointes have been reported. 
V zelo redkih primerih so poročali o ventrikularni aritmiji, podaljšanju QT intervala in “torsades de pointes”.
Very rare: erythema nodosum, erythema multiforme (minor), Stevens-Johnson syndrome, epidermal necrolysis (Lyell Syndrome). 
Zelo redki: nodozni eritem, multiformni eritem (minor), Stevens-Johnsonov sindrom, epidermalna nekroliza (Lyellov sindrom).
• bone infections. 
• okužbah kosti
The interaction between theophylline and ciprofloxacin is potentially life-threatening. 
Interakcija teofilina in ciprofloksacina je potencialno smtno nevarna.
Photosensibility: 
Fotosenzibilnost:
The following indications can be considered for treatment with Ciprofloxacin Kabi when oral therapy is not possible or not reliable: - complicated urinary tract infections - infections of the lower respiratory tract including pneumonia caused by aerobic gram-negative bacteria, in case of Streptococcus pneumoniae infections ciprofloxacin is not the substance of first choice. 
Zdravljenje s Ciprofloxacinom Kabi pride v poštev pri naslednjih indikacijah, če peroralno zdravljenje ni mogoče ali ni zanesljivo: - zapletenih okužbah sečil, - okužbe spodnjih dihal, vključno s pljučnicami, ki jih povzročajo aerobne gramnegativne bakterije; v primeru okužb s Streptococcus pneumoniae, ciprofloksacin ni zdravilo prve izbire.
Ciprofloxacin, like other quinolones, may enhance the effect of coumarin derivates including warfarin. 
Ciprofloksacin tako kot ostali kinoloni lahko poveča učinek kumarinskih derivatov vključno z varfarinom.
Due to the risk of arthropathy and other potentially severe toxicity in the infant, ciprofloxacin is contraindicated during lactation (see section 4.3). 
Zaradi tveganja za artropatijo in druge potencialno hude toksične učinke pri otroku je dojenje med zdravljenjem s ciprofloksacinom kontraindicirano (glejte poglavje 4.3).
Concentrations in pulmonary tissue, gynaecological tissue and prostate tissue and fluid were also significantly higher than the serum concentration. 
Tudi koncentracije v pljučnem tkivu, ginekološkem tkivu, tkivu prostate in prostatični tekočini so bile pomembno višje od koncentracije v serumu.
Musculoskeletal system: 
Mišično-skeletni sistem:
• convulsions (seizures), epilepsy or another brain disease, for example decreased blood circulation in the brain, stroke or increased sensitivity to convulsions, since possible side effects of ciprofloxacin may cause damage to the brain. 
• Konvulzije (napad krčev), epilepsija ali druga možganska bolezen, na primer zmanjšan krvni pretok v možganih, možganska kap ali povečana občutljivost za konvulzije, ker lahko morebitni neželeni učinki ciprofloksacina poškodujejo možgane;
However, if this is not possible the patient is recommended to use a sun-protection cream. 
Če to ni mogoče, naj uporabljajo kremo za sončenje.
In case of very severe infections the dose can be increased up to a maximum daily dose of 1200 mg (400 mg thrice daily). 
Pri zelo hudih okužbah se lahko odmerek poveča do največjega dnevnega odmerka 1200 mg (400 mg trikrat na dan).
Patients with a family history of or actual defects in glucose-6-phosphate dehydrogenase activity are prone to haemolytic reactions with quinolones, and so ciprofloxacin should be used with caution in these patients. 
Bolniki z družinsko anamnezo motenj aktivnosti glukoza-6-fosfat dehidrogenaze so nagnjeni k hemolitičnim reakcijam s kinoloni in zato je treba ciprofloksacin pri teh bolnikih dajati s previdnostjo.
After oral administration 45% is excreted unchanged in the urine and 25% is excreted in the faeces. 
Po peroralni uporabi se ga 45 % izloči nespremenjenega v urinu, 25 % pa se ga izloči v blatu.
Rare: transpiration. 
Redki: znojenje.
The blood level of this medicine can be increased or reduced. 
Koncentracija tega zdravila v krvi se lahko zviša ali zniža;
• complicated skin and soft tissue infections 
• zapletenih okužbah kože in mehkih tkiv
This applies to gall, kidney, gall bladder and liver tissue. 
To velja za žolč, ledvice, žolčnik in jetrno tkivo.
Impaired renal function: In patients with a creatinine clearance in the range 31 - 60 ml/minute/1.73 m2 or a serum creatinine concentration in the range 124 - 174 µmol/l, the maximum daily intravenous dose is 800 mg. 
Okvarjeno delovanje ledvic: Pri bolnikih z očistkom kreatinina od 31 - 60 ml/min/1,73 m2 ali koncentracijo kreatinina v serumu v obsegu 124 - 174 µmol/l, je največji dnevni intravenski odmerek 800 mg.
Simultaneous administration of ciprofloxacin and phenytoin may result in increased or reduced serum levels of phenytoin such that monitoring of drug levels is recommended. 
Sočasno dajanje ciprofloksacina in fenitoina lahko ima za posledico povečanje ali zmanjšanje ravni fenitoina v serumu zato se priporoča nadziranje ravni zdravila.
ESBL: Extended Spectrum Beta-lactamases MRSA: Methicillin-resistant Staphylococcus aureus 
ESBL: beta-laktamaze razširjenega spektra MRSA: proti meticilinu odporni Staphylococcus aureus
If you experience these symptoms you should immediately consult your doctor and rest the respective leg. 
• Če imate te simptome, se takoj posvetujte z zdravnikom, prizadeta noga pa naj miruje;
Do not use Ciprofloxacin Kabi after the expiry date which is stated on the packaging after “Exp”. 
Zdravila Ciprofloxacin Kabi ne smete uporabljati po datumu izteka roka uporabnosti, ki je naveden na ovojnini poleg oznake “Exp”.
BATCH NUMBER Batch (number) 
ŠTEVILKA SERIJE Serija (številka)
Especially patients undergoing long-term treatment (e.g. in cystic fibrosis, osteomyelitis), or patients who are extremely susceptible to infections (e.g. in selective prophylaxis in certain groups of neutropenic patients, artificial ventilation) show the highest risk. 
Tveganje je največje še posebno pri bolnikih, ki so podvrženi dolgotrajnemu zdravljenju (npr. bolniki s cistično fibrozo, osteomielitisom), in bolnikih, ki so izredno dovzetni za okužbe (npr. selektivna profilaksa pri določenih skupinah nevtropeničnih bolnikov, umetna ventilacija).
Keep infusion bag in the overpouch until ready to use in order to protect from light. 
Infuzijska vrečka naj ostane v zunanjem ovoju, dokler ni pripravljena za uporabo, za zagotovitev zaščite pred svetlobo.
A larger number of metabolites after oral administration indicates some degree of first-pass metabolism, mainly forming sulphociprofloxacin. 
Večje število presnovkov po peroralni uporabi nakazuje določeno mero presnove prvega prehoda, v kateri nastane predvsem sulfociprofloksacin.
If nevertheless complaints occur, such as fever, rash, itching, small red spots on the skin, you should consult your doctor since the treatment may need to be discontinued. 
• Če se kljub temu pojavijo težave, kot so povečana telesna temperatura, izpuščaj, srbenje, majhne redeče pike na koži, se posvetujte z zdravnikom, saj bo morda treba zdravljenje prekiniti;
- complicated skin and soft tissue infections - osteomyelitis 
- zapletenih okužbah kože in mehkih tkiv, - osteomielitisu.
• oral anticoagulants (used to prevent blood from clotting, e.g. warfarin). 
• Peroralni antikoagulanti (uporabljajo se za preprečevanje strjevanja krvi, npr. varfarin).
NL-5202 CJ´s Hertogenbosch, Netherlands 
NL-5202 CJ´s Hertogenbosch, Nizozemska
In juvenile and prenatal animals exposed to quinolones effects on immature cartilage have been observed. 
Pri mladih in prenatalnih živalih, izpostavljenih kinolonom, so ugotovili učinke na nezrelem hrustancu.
Animal experiments have shown that ciprofloxacin passes the placenta and is excreted in breast milk. 
Poskusi na živalih so pokazali, da ciprofloksacin prehaja skozi placento in se izloča v materinem mleku.
If there is any indication of tendinitis (e.g. painful swelling) the administration of ciprofloxacin or other fluoroquinolones must immediately be discontinued, the affected extremity should not be strained and a physician must be consulted. 
Če se pojavijo kakršnikoli znaki tendinitisa (npr. boleča oteklina), je treba uporabo ciprofloksacina ali drugih fluorokinolonov takoj prekiniti, prizadete ekstremitete pa se ne sme obremenjevati.
The solution for infusion should be administered over an infusion period of 60 minutes. 
Raztopino za infundiranje je treba dajati 60 minut.
Enterococcus faecium Staphylococcus epidermidis Staphylococcus haemolyticus Gram-negative aerobes E. coli multi-resistant Providencia spp. 
Enterococcus faecium Staphylococcus epidermidis Staphylococcus haemolyticus Gramnegativni aerobi E. coli multi-resistant Providencia spp.
The treatment was well tolerated, the most commonly occurring adverse event were gastrointestinal disorders. 
Bolniki so zdravljenje dobro prenašali, najpogostejši neželeni učinek so bile prebavne motnje.
In this section undesirable effects are defined as follows: 
Pogostnost neželenih učinkov je razvrščena v naslednje skupine:
• caffeine (used as a stimulant), pentoxifylline (used to treat circulatory disorders in the limbs) and mexiletine (used to treat irregular heart beat). 
• Kofein (uporablja se kot stimulans), pentoksifilin (za zdravljenje motenj krvnega obtoka v okončinah) in meksiletin (za zdravljenje nepravilnega srčnega utripa).
- The body of published literature and resistance data presented provide adequate justification, both from an efficacy and safety viewpoint, for the dosing regimen of 200-400 mg ciprofloxacin twice daily for the treatment of complicated UTI. 
- Predstavljena objavljena literatura in podatki o odpornosti so s stališča učinkovitosti in varnosti zadostna utemeljitev za zdravljenje zapletenih okužb sečil z odmerki 200-400 mg ciprofloksacina dvakrat dnevno.
He/she may find it necessary to adjust your dose due to a reduced kidney function. 
Morda bo ugotovil, da je treba odmerek zaradi poslabšanega delovanja ledvic prilagoditi.
Oral administration of 20 mg/kg twice daily to children with cystic fibrosis gives an exposure that is comparable to that in adults following an oral dose of 750 mg twice daily. 
Peroralno dajanje je 20 mg/kg dvakrat dnevno pri otrocih s cistično fibrozo, ki je primerljivo z odmerjanjem pri odraslih peroralnega odmerka 750 mg dvakrat dnevno.
If such reactions occur, treatment with ciprofloxacin must be discontinued immediately and the treating physician informed. 
Če se pojavijo takšne reakcije, je treba zdravljenje s ciprofloksacinom takoj prekiniti in obvestiti lečečega zdravnika.
Uncommon: eosinophilia, leukopenia. 
Občasni: eozinofilija, levkopenija.
[See Annex I - To be completed nationally] 
[glejte Dodatek I - izpolni država članica]
Metabolism and nutrition disorders: Rare: hyperglycaemia. 
Presnovne in prehranske motnje: Redki: hiperglikemija.
Signs of these reactions are: a sharp drop in blood pressure, paleness, restlessness, weak/rapid pulse, clammy skin, dizziness. 
Znaki teh reakcij so: hitro znižanje krvnega tlaka, bledica, nemir, šibek/hiter utrip, vlažna koža, omotica.
• theophylline (used to treat asthma), clozapine (used to treat schizophrenia), tacrine (used to treat symptoms of Alzheimer´s disease), ropinirol (used to treat Parkinson disease) and tizanidine (used to treat muscle spasms). 
• Teofilin (za zdravljenje astme), klozapin (za zdravljenje shizofrenije), takrin (za zdravljenje simptomov Alzheimerjeve bolezni), ropinirol (za zdravljenje Parkinsonove bolezni) in tizanidin (za zdravljenje mišičnih krčev).
When during or after the treatment with ciprofloxacin or another fluoroquinolone severe and persistent diarrhoea occurs, pseudomembranous colitis must be taken into account (life-threatening with possibly fatal outcome). 
Če se med zdravljenjem s ciprofloksacinom ali kakšnim drugim fluorokinolonom ali po takšnem zdravljenju pojavi huda in dolgotrajna driska, je treba upoštevati možnost psevdomembranskega kolitisa (ki je smrtno nevaren in se lahko konča usodno).
In the case of concomitant administration of these products, prothrombin time (PT) or other suitable coagulation tests should be monitored. 
V primeru sočasne uporabe ciprofloksacina in peroralnih antikoagulantov je treba nadzorovati protrombinski čas ali druge ustrezne teste koagulacije.
Therefore the amount of these other medicines may rise in the blood. 
Zato se lahko količina teh zdravil v krvi poveča;
Inherently resistant organisms Gram-positive aerobes Enterococcus spp. 
Inherentno rezistentni mikroorganizmi Grampozitivni aerobi Enterococcus spp.